| 產(chǎn)品編號 | bs-19000R-Gold |
| 英文名稱1 | Rabbit Anti-NAF1/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的核組裝因子1核糖核蛋白抗體 |
| 別 名 | H/ACA ribonucleoprotein complex non-core subunit NAF1; hNAF1; Naf1; NAF1_HUMAN; Nuclear assembly factor 1 homolog; Nuclear assembly factor 1 ribonucleoprotein. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領域 | 細胞生物 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, ) |
| 產(chǎn)品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 54kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human NAF1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: NAF1 is a 494 amino acid RNA-binding protein belonging to the NAF1 family. Encoded by a gene that maps to human chromosome 4q32.2, NAF1 associates with mature RNA in cell lysates and is essential for ribosome biogenesis, premessenger RNA splicing, stable RNA accumulation, maturation of box snoRNP complexes and telomere maintenance. NAF1 mobilizes at the site of transcription where it binds to and escorts the core protein Dyskerin between the nucleus and cytoplasm. NAF1 is replaced by GAR1, which binds competitively with NAF1, resulting in mature RNPs in Cajal bodies and nucleoli. NAF1 delocalizes to the cytoplasm during overexpression but NAF1 shuttling properties continue to be operative. Dyskeratosis congenita mutations in human telomerase RNA may affect NAF1 assembly function. Function: Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD1 is a receptor-regulated SMAD (R-SMAD). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. Subunit: Interacts with HGS, NANOG and ZCCHC12 By similarity. May form trimers with another SMAD1 and the co-SMAD SMAD4. Interacts with PEBP2-alpha subunit, CREB-binding protein (CBP), p300, SMURF1, SMURF2, USP15 and HOXC8. Associates with ZNF423 or ZNF521 in response to BMP2 leading to activate transcription of BMP target genes. Interacts with SKOR1. Interacts (via MH2 domain) with LEMD3. Binding to LEMD3 results in at least a partial reduction of receptor-mediated phosphorylation. Forms a ternary complex with PSMB4 and OAZ1 before PSMB4 is incorporated into the 20S proteasome. Subcellular Location: Cytoplasm. Nucleus. Shuttles between the cytoplasm and the nucleus. Absent from the nucleolus. Tissue Specificity: Ubiquitous. Highest expression seen in the heart and skeletal muscle. Post-translational modifications: Phosphorylated on serine by BMP type 1 receptor kinase. Ref.11 Ref.22 Ubiquitinated by SMAD-specific E3 ubiquitin ligase SMURF1, leading to its degradation. Monoubiquitinated, leading to prevent DNA-binding. Deubiquitination by USP15 alleviates inhibition and promotes activation of TGF-beta target genes. DISEASE: SMAD1 variants may be associated with susceptibility to pulmonary hypertension, a disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs. Similarity: Belongs to the dwarfin/SMAD family. Contains 1 MH1 (MAD homology 1) domain. Contains 1 MH2 (MAD homology 2) domain. Database links: Entrez Gene: 92345 Human Entrez Gene: 461581 Chimpanzee SwissProt: Q96HR8 Human Unigene: 129095 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
